PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer

Sponsors of PD-1 inhibitors pushed further into new indications for monotherapy and combinations in bladder and head and neck cancers with data presentations at the Society for Immunotherapy of Cancer meeting.

Lung cancer represents the biggest market for PD-1 and PD-L1 inhibitors, and has dominated recent headlines, but other smaller markets offer opportunities to build sales and collectively contribute to revenue...